These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 31033568)

  • 21. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population.
    Cuzick J; Cadman L; Ahmad AS; Ho L; Terry G; Kleeman M; Lyons D; Austin J; Stoler MH; Vibat CRT; Dockter J; Robbins D; Billings PR; Erlander MG
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1053-1059. PubMed ID: 28223432
    [No Abstract]   [Full Text] [Related]  

  • 23. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
    Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
    BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.
    Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ
    Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Hammer A; Demarco M; Campos N; Befano B; Gravitt PE; Cheung L; Lorey TS; Poitras N; Kinney W; Wentzensen N; Castle PE; Schiffman M
    Int J Cancer; 2020 Sep; 147(6):1612-1620. PubMed ID: 32141607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of HPV-16/18 genotypes and immediate histopathologic correlation results in a Chinese population with negative cytology and positive high-risk HPV testing.
    Tao X; Zhang H; Li J; Zhang H; Xiao J; Zhang L; Zhou X; Sui L; Wang L; Zhao C
    Cancer Cytopathol; 2019 Oct; 127(10):650-657. PubMed ID: 31532582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution, and correlation with cervical cytology.
    Ali MAM; Bedair RN; Abd El Atti RM
    Cancer Cytopathol; 2019 Sep; 127(9):567-577. PubMed ID: 31390155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma screening in a population with a low incidence of cervical carcinoma.
    Petignat P; Faltin D; Goffin F; Billieux MH; Stucki D; Sporri S; Vassilakos P
    Cancer; 2005 Jun; 105(3):126-32. PubMed ID: 15822123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep Papanicolaou cytology.
    Bansal M; Zhao C
    J Low Genit Tract Dis; 2011 Apr; 15(2):105-9. PubMed ID: 21317806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening.
    Isidean SD; Wang Y; Mayrand MH; Ratnam S; Coutlée F; Franco EL; Abrahamowicz M;
    Int J Cancer; 2019 May; 144(10):2408-2418. PubMed ID: 30411802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.
    Leinonen MK; Anttila A; Malila N; Dillner J; Forslund O; Nieminen P
    Br J Cancer; 2013 Nov; 109(11):2941-50. PubMed ID: 24136148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
    Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
    BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoption of HPV testing as an adjunct to conventional cytology in cervical cancer screening in Japan.
    Inoue M; Okamura M; Hashimoto S; Tango M; Ukita T
    Int J Gynaecol Obstet; 2010 Nov; 111(2):110-4. PubMed ID: 20708184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.
    Wang HY; Lee D; Park S; Kim G; Kim S; Han L; Yubo R; Li Y; Park KH; Lee H
    Asian Pac J Cancer Prev; 2015; 16(17):7633-40. PubMed ID: 26625774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prevalence and significance of high-risk human papillomavirus DNA test in southern Malaysia and Singapore.
    Tay SK; Tay YK
    Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):323-7. PubMed ID: 19566569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.